USP: Third Instrument Qualification Stimuli published for Comments

Recommendation
Tuesday, 23 September 2025 13.00 - 17.00 h
As of early September 2022, the stimuli document "Analytical Instrument and System (AIS) Qualification: The Qualification Life Cycle Process" has been posted on the USP Pharmacopeial Forum website for comment. Remarks and comments on this draft may be submitted until November 30, 2022.
This draft is divided into the following chapters and subchapters:
- Introduction
- Life Cycle Process Descriptions
o User Requirement Specifications
o Vendor Contribution to the Qualification Process
o Design Qualification
o Purchase Order
o Installation Qualification
o Operational Qualification
o Performance Qualification
o Qualification Summary Report
o Operational Use and System Suitability Tests
o New Analytical Procedures
o Ongoing Performance Verification of the Qualified State - Conflict of Interest Disclaimer
- References
You can get to and comment the Stimuli document "Analytical Instrument and System (AIS) Qualification: The Qualification Life Cycle Process" after a one-time registration on the Pharmacopeial Forum website.
Here you can also view the previous Stimuli articles on "Analytical Instrument and System (AIS) Qualification, to support Analytical Procedure Validation over the Life Cycle- PF 48(1)" and "Measurement Uncertainty Evaluation Relevant to Analytical Instrument and System (AIS) Qualification - The Role of Measurement Uncertainty Concepts within the AIS - PF 48(2)", which were available for comments earlier this year.
Related GMP News
14.07.2025Inadequate Sampling and Component Testing Highlighted in FDA Warning Letter
14.07.2025EMA publishes new Product-Specific Bioequivalence Guidance
14.07.2025Revision of USP Chapter <1039> Chemometrics Published for Comments
14.07.2025Proposal for new USP Chapter <318> NMR Monomer Ratio Determination for Lactide-Glycolide Polymers
14.07.2025New USP Chapter <1221> on Ongoing Procedure Performance Verification (OPPV) Published for Comment
02.07.2025FDA Warning Letter: Missing Testing, No Stability Data, and Inadequate Raw Material Controls